Trials / Completed
CompletedNCT00643643
Pharmacokinetics, Pharmacodynamics, And Safety Of Maraviroc (UK-427,857) In Patients With Human Immunodeficiency Virus
A Randomised, Double Blind, Placebo-Controlled, Multicentre Study Of UK-427,857 25mg O.D. , 50mg B.I.D., 100mg B.I.D And 300mg B.I.D. In Asymptomatic HIV Infected Patients To Investigate Pharmacodynamics, Pharmacokinetics, Safety And Toleration.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 41 (actual)
- Sponsor
- ViiV Healthcare · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Not accepted
Summary
To investigate the relationship between the pharmacokinetics and pharmacodynamics of UK-427,857 and its antiviral effects in patients with human immunodeficiency virus (HIV).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Maraviroc (UK-427,857) | 25 mg oral tablet once daily for 10 days |
| DRUG | Maraviroc (UK-427,857) | 50 mg oral tablet twice daily for 10 days |
| DRUG | Maraviroc (UK-427,857) | 100 mg oral tablet twice daily for 10 days |
| DRUG | Maraviroc (UK-427,857) | 300 mg oral tablet twice daily for 10 days |
| OTHER | Placebo | Matching placebo oral tablet twice daily for 10 days |
Timeline
- Start date
- 2002-10-01
- Primary completion
- 2003-06-01
- Completion
- 2003-06-01
- First posted
- 2008-03-26
- Last updated
- 2010-11-10
Locations
6 sites across 3 countries: Germany, Netherlands, United Kingdom
Source: ClinicalTrials.gov record NCT00643643. Inclusion in this directory is not an endorsement.